Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial of terguride in diffuse cutaneous systemic sclerosis
2015-002586-39Phase 3Terminated
- Sponsor
- medac GmbH
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diffuse cutaneous systemic sclerosis (dcSSc) and systemic sclerosis (SSc) comparing terguride with placebo (2 arms). Primary endpoint: Change in modified Rodnan skin score at Week 52. Started Jun 2016; status: terminated.
02
Drugs
terguride
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)systemic sclerosis (SSc)
Beyond the preview
Go deeper on 2015-002586-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002586-39.